Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Priority to CU20100011ApriorityCriticalpatent/CU20100011A7/en
Publication of CU20100011A7publicationCriticalpatent/CU20100011A7/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Los compuestos de la fórmula (I): ESPACIO PARA LA FÓRMULA en forma libre o de sal o de solvato, en donde R1, R2 y R5 tienen los significados indicados en la memoria descriptiva, son útiles para el tratamiento de las enfermedades mediadas por el receptor de ALK-5 y/o ALK-4. También se describen composiciones farmacéuticas que contienen los compuestos, y procesos para la preparación de estos compuestos.The compounds of the formula (I): SPACE FOR FORMULA in free or salt or solvate form, where R1, R2 and R5 have the meanings indicated in the specification, are useful for the treatment of diseases mediated by ALK-5 and / or ALK-4 receiver. Also described are pharmaceutical compositions containing the compounds, and processes for the preparation of these compounds.